NEW YORK, April 17, 2017 /PRNewswire/ --
Stock-Callers.com today has issued research reports on Centene Corp. (NYSE: CNC), Anthem Inc. (NYSE: ANTM), ICON PLC (NASDAQ: ICLR), and Nobilis Health Corp. (NYSE MKT: HLTH). These are stocks that operate in the Healthcare sector, which includes companies that are involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. Learn more about these stocks by downloading their comprehensive and free reports at:
Last Thursday at the close, shares in St. Louis, Missouri headquartered Centene Corp. ended 0.45% lower at $70.56. The stock recorded a trading volume of 772,181 shares. The Company's shares have advanced 2.92% in the last one month, 12.52% in the previous three months, and 24.86% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.58% and 7.78%, respectively. Furthermore, shares of Centene, which operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the US, have a Relative Strength Index (RSI) of 50.52.
On April 05th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $84 per share. CNC complete research report is just a click away and free at:
Indianapolis, Indiana headquartered Anthem Inc.'s stock finished Thursday's session 0.87% lower at $164.99 with a total trading volume of 1.26 million shares. The Company's shares have advanced 11.77% over the previous three months and 15.21% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.48% and 17.47%, respectively. Additionally, shares of Anthem, which through its subsidiaries, operates as a health benefits company in the US, have an RSI of 47.82.
On April 04th, 2017, Anthem announced that it will release Q1 2017 financial results on April 26th, 2017, at 6:00 a.m. ET. Management will review these results and its outlook during a conference call at 8:30 a.m. ET that same morning. The call will be available through a live webcast under the "Investors" link of the Company's website. A webcast replay will be available following the call.
On April 05th, 2017, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, with a target price of $166 per share. The complimentary report on ANTM can be downloaded at:
Shares in Dublin, Ireland headquartered ICON PLC ended the session 1.26% lower at $77.58 with a total trading volume of 175,928 shares. The stock has gained 3.16% on an YTD basis. The Company's shares are trading below their 200-day moving average by 0.68%. Moreover, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the US, and internationally, have an RSI of 33.26.
On March 23rd, 2017, research firm Mizuho initiated a 'Neutral' rating on the Company's stock, with a target price of $66 per share.
On April 12th, 2017, ICON announced that it has been awarded Best Clinical Research Organization at the Vaccine Industry Excellence Awards. The Company was presented with the award at the World Vaccine Congress, which took place in Washington on the same week. Sign up for your complimentary research report on ICLR at:
Houston, Texas headquartered Nobilis Health Corp.'s shares recorded a trading volume of 411,017 shares, and closed 3.70% lower at $1.30. The stock is trading 30.92% below its 50-day moving average. Shares of the Company, which together with its subsidiaries, acquires and manages ambulatory surgical centers and healthcare facilities in the US, have an RSI of 24.00.
On March 20th, 2017, Nobilis Health announced the appointment of Marc Celia as the Company's Executive Vice President of Operations. Mr. Celia will be responsible for operations of all Nobilis facilities, working directly with facility CEOs and administrators to promote improved individual center and organization-wide efficiencies. Get free access to your research report on HLTH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA